How a long shot ALS drug came before the FDA
BioPharma
Stay updated with breaking news from Michael Benatar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Neuvivo today announced the publication of a paper on its lead candidate drug NP001 for the treatment of ALS in the peer-reviewed journal...
The discovery and validation of potential disease progression biomarkers has been one of the top priorities in ALS/MND research. An international
An international collaboration led by Flinders University has identified a potential biomarker for amyotrophic lateral sclerosis, also known as Motor Neuron Disease, providing a way to test the effectiveness of future clinical trials.
May 4, 2021 The key to optimal treatment of amyotrophic lateral sclerosis (ALS) may be to initiate treatment before symptoms emerge—a difficult, but intriguing, hypothesis that will soon be tested in a clinical trial. That trial, known as ATLAS, will evaluate the best timing to begin treatment with the investigational antisense oligonucleotide tofersen in presymptomatic SOD1 mutation carriers at high risk for ALS. The ATLAS trial will assess levels of the axonal injury marker neurofilament light (NfL) to identify imminent phenoconversion in superoxide dismutase 1 ( SOD1) mutation carrier...